

NOTICE

END OF ALTERNATIVE MEDICATION AUTHORIZATION

An Act respecting prescription drug insurance (chapter A-29.01, s. 60.1)

The following medication:

| | | | | | | | |
|----------|----------------------|--|---|--------|-----------|--|--|
| 99101372 | <i>Sulfasalazine</i> | | 1 | 500 mg | Ent. Tab. | | |
|----------|----------------------|--|---|--------|-----------|--|--|

is no longer authorized as an alternative for the following medication, which is once again available:

| | | | | | | | |
|----------|-------------------------------|-----------|-----|--------|-----------|--------|--------|
| 00598488 | <i>pms-Sulfasalazine-E.C.</i> | Phscience | 100 | 500 mg | Ent. Tab. | 28.16 | 0.2816 |
| | | | 500 | 500 mg | | 140.80 | 0.2816 |

This notice has effect from 29 September 2017.

Québec, 27 September 2017

Original signed by :

PAUL MARCEAU
Interim President and Chief Executive Officer
Régie de l'assurance maladie du Québec

Publication of this notice on the website of the Régie de l'assurance maladie du Québec imparts authentic value to it.